Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 10, 2022 (4 years ago)

PF-Neostigmine Methylsulfate Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Potential for cross contamination due to product carry over.

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension West Columbia, SC 29172, NDC 69374-932-33, UPC 3 69374-93233 2.

Affected NDC 69374-0932-33

Compare with the code on your package — it is the most precise check available.

Drug: Neostigmine

Recalling firm
Nephron Sterile Compounding Center LLC
NDC code
69374-932-33
Origin
SC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0065-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Neostigmine recalls

See all
Class II · Moderate risk

neostigmine 5 mg/5mL

Lack of assurance of sterility. Validation data for decontamination cycles is lacking.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. D-0982-2023

Other recalls by Nephron Sterile Compounding Center LLC

All 2022 recalls